Checking HLA antibody results in people with lupus
Official title: HLA Antibodies in Systemic Lupus Erythematosus
Run by Centre Hospitalier Universitaire, Amiens · NCT06921239 · Data updated 2026-11-12
This project will test how often people with lupus have false-positive anti-HLA antibody results and try lab methods to rule out those false positives.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens) |
| Status | Recruiting |
| Started | February 10, 2025 |
| Main results expected | November 2026 |
| Study ends | May 2027 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT06921239 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with systemic lupus erythematosus who are followed in the internal medicine department at Amiens University Hospital and have serum stored in the hospital biobank, with no history of pregnancy, transfusion, or transplant.
✕Probably not a fit
Children, people without stored sera, or those with prior pregnancies, transfusions, or transplants are not eligible and may not benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will analyze stored serum samples from adult patients with systemic lupus erythematosus followed at Amiens University Hospital who have no history of pregnancy, transfusion, or transplant. Investigators will measure the prevalence of false-positive anti-HLA antibody detections in this lupus cohort and apply laboratory techniques intended to negate or identify those false positives. The work uses existing biobank samples and standard immunogenetics assays modified as needed to distinguish true anti-HLA sensitization from artefactual reactivity. Results will be descriptive and aimed at improving interpretation of HLA testing for transplant compatibility in autoimmune patients.
Why it matters
Potential benefit: If successful, this could reduce false-positive HLA results and help more lupus patients be accurately considered for organ transplantation.
How similar studies have gone: Previous reports have documented false-positive HLA antibody results in autoimmune patients and some laboratory methods (for example adsorption or modified assay protocols) have reduced such reactivity, but data specifically focused on lupus cohorts remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients Adults * Followed in the internal medicine department of Amiens University Hospital - With systemic lupus erythematosus * Without HLA immunization risk factors (no history of pregnancy, transfusions or transplants) * With sera stored in the biobank Exclusion Criteria: * minor Patients * Opposing the re-use of their personal data for research purposes
Where it's running
-
CHRU Amiens
Amiens, France Recruiting
Study contacts
- Study coordinator: Nicolas GUILLAUME, Pr
- Email: guillaume.nicolas@chu-amiens.fr
- Phone: 33+322087046
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of anifrolumab on arterial inflammation in SLE patients
This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.
-
Home urine testing for people with lupus
Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
-
Biomarker tests in adults with lupus to see how kidney disease changes over time
Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.
-
Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia
This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.